Trial intelligence / Profile preview

EMINENT CD mirikizumab trial in Crohn's disease

2025-521889-95-00Phase 4Authorised

Sponsor: GETAID
Start: May 2026
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 4, open-label, single-arm trial of mirikizumab in Crohn's disease, sponsored by GETAID. Primary endpoint: Transmural response (TR25) at week 24. Planned start May 2026; status: authorised.

Drugs

mirikizumab

Conditions

Crohn's disease

Beyond the preview

Go deeper on 2025-521889-95-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-521889-95-00.